Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2012-09-21 Transaction in Own Shar…
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Transaction in Own Shares 2012
Transaction in Own Shares Classification · 99% confidence The document explicitly details transactions made under a share buyback program ('aktietilbagekøbsprogram') initiated on January 20, 2012, and reports the number of own shares held ('I alt ejer Novozymes i alt 12.276.984 egne aktier'). This content directly corresponds to the definition of a report concerning the company buying back or selling its own shares. Therefore, the appropriate classification is Transaction in Own Shares (POS). The document is a detailed report, not just an announcement of a report's publication.
2012-09-21 English
Transaction in Own Shares 2012
Transaction in Own Shares Classification · 100% confidence The document text is very short (237 characters) and explicitly states that the full announcement is available in PDF format ("Læs hele meddelsen i pdf format."). This strongly suggests it is an announcement about the availability of a filing, rather than the filing itself. The content discusses an 'aktietilbagekøbsprogram' (share buyback program) under a specific EU regulation. A share buyback program falls under the category of the company transacting in its own shares. Therefore, the most specific classification is Transaction in Own Shares (POS). Given the short length and reference to a PDF, it is likely an announcement of this transaction, which aligns with POS, or potentially RNS if POS is too specific for an announcement wrapper, but POS is the core topic. Since POS covers the transaction itself, and this is an announcement of that transaction, POS is the best fit among the specific options, although RPA or RNS could also be argued if the text was purely about the publication timing. Since the subject matter is clearly defined as a share repurchase, POS is chosen.
2012-09-21 Danish
Transaction in Own Shares 2012
Transaction in Own Shares Classification · 100% confidence The document explicitly states that 'Novozymes initiated a share buyback program' and details the amount (DKK 1,000 million) and period (Jan 20, 2012, to Dec 31, 2012) for buying back B shares. This directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase programs. Although it mentions reading the full announcement in PDF, the core content is the initiation and details of the buyback, making POS the most specific fit over a general RPA or RNS.
2012-09-14 English
Transaction in Own Shares 2012
Transaction in Own Shares Classification · 99% confidence The document details specific transactions made by Novozymes under a previously announced share buyback program (aktietilbagekøbsprogram) governed by EU regulation 2273/2003. It provides a running total of shares bought back and the current holding of treasury shares. This content directly relates to the company managing its own stock, which falls under the definition of 'Transaction in Own Shares' (POS). The document is a formal report of these transactions, not just an announcement of a report (RPA/RNS).
2012-09-14 English
Major Shareholding Notification 2012
Major Shareholding Notification Classification · 98% confidence The document explicitly states that Novozymes has been informed of a decrease in the holding of B shares by Baillie Gifford & Co, which constitutes a change in significant share ownership. This directly maps to the Major Shareholding Notification (MRQ) definition. Although the text mentions reading the full announcement in PDF format, the core content is the notification of the shareholding change itself, making MRQ the most specific fit over a general RPA or RNS.
2012-09-12 English
Director's Dealing 2012
Director's Dealing Classification · 98% confidence The document explicitly states that Novozymes was informed that Baillie Gifford & Co decreased its holding of B shares in Novozymes, detailing the new percentage (7.64%) and the number of shares held. This type of disclosure, reporting changes in significant share ownership by an investor, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is short and is a direct notification, not an announcement of a larger report.
2012-09-12 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.